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Abstract
Background: To test a hypothesis that in negative clinical trials of erythropoietin in patients with acute myocardial
infarction (MI) the erythropoietin (rhEPO) could be administered outside narrow therapeutic window. Despite
overwhelming evidence of cardioprotective properties of rhEPO in animal studies, the outcomes of recently concluded
phase II clinical trials have failed to demonstrate the efficacy of rhEPO in patients with acute MI. However, the time between
symptoms onset and rhEPO administration in negative clinical trials was much longer that in successful animal experiments.
Methodology/Principal Findings: MI was induced in rats either by a permanent ligation of a descending coronary artery or
by a 2-hr occlusion followed by a reperfusion. rhEPO, 3000 IU/kg, was administered intraperitoneally at the time of
reperfusion, 4 hrs after beginning of reperfusion, or 6 hrs after permanent occlusion. MI size was measured histologically
24 hrs after coronary occlusion. The area of myocardium at risk was similar among groups. The MI size in untreated rats
averaged ,42% of area at risk, or ,24% of left ventricle, and was reduced by more than 50% (p,0.001) in rats treated with
rhEPO at the time of reperfusion. The MI size was not affected by treatment administered 4 hrs after reperfusion or 6 hrs
after permanent coronary occlusion. Therefore, our study in a rat experimental model of MI demonstrates that rhEPO
administered within 2 hrs of a coronary occlusion effectively reduces MI size, but when rhEPO was administered following a
delay similar to that encountered in clinical trials, it had no effect on MI size.
Conclusions/Significance: The clinical trials that failed to demonstrate rhEPO efficacy in patients with MI may have missed a
narrow therapeutic window defined in animal experiments.
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Introduction
During the last decade powerful cardioprotective properties of
exogenous recombinant human erythropoietin (rhEPO) have been
demonstrated in numerous experimental studies of two different
models of myocardial infarction (MI), a permanent coronary
ligation and ischemia/reperfusion model, in several species [1–6].
Despite positive outcomes observed in vast majority of animal
experiments, the results of several, phase II, clinical trials in
humans concluded recently (Table 1) were far less than
encouraging [7–19]. In fact, in an editorial in JAMA [20] written
in conjunction with publication of results of the recent clinical trial
with a negative outcome, ‘‘Reduction of Infarct Expansion and
Ventricular Remodeling With Erythropoietin After Large Myo-
cardial Infarction’’ [18], recommended that no future clinical trials
of EPO should be undertaken. Moreover, it implied that
frequently occurring discrepancies between successful animal
experiments and negative outcomes of clinical trials in humans,
in context of reduction of MI size, make it impractical to conduct
clinical trials based on animal studies; but rather promising new
therapies should be screened in small number of patients.
But what if a main reason for failure to translate animal
experiment findings into a clinical application was not due to
fundamental differences between human and animal species in
response to EPO but rather due to differences in designs between
preclinical (animal) and clinical (human) trials. An analysis of
literature on animal experiments related to myocardial protection
from ischemic damage by erythropoietin [1–6], as well as
dissection of details of design of several completed clinical trials
[7–19], clearly indicates that most of these clinical trials have a
common trend – the time interval between presumed occlusion of
a coronary artery (onset of symptoms) and drug administration
was much greater in human clinical trials with a negative outcome
than described in any animal experiment with a positive outcome.
Thus, in the case of erythropoietin in patients with an acute MI, a
reason why rhEPO was ineffective to reduce an MI size may have
been the delay in drug administration. We investigated the role of
such a delay in therapy in two rat models of MI induced by a
permanent or temporary ligation of a coronary artery, in which we
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34819followed the design of the last clinical trial, REVEAL [17,18].
Specifically, we compared the MI size among three different
situations: when the bolus injections of rhEPO were administered
systemically into rats either 2 hours after coronary ligation at the
time of reperfusion, or 4 hours after reperfusion that followed
2 hours of coronary occlusion, or 6 hours after permanent
coronary occlusion without reperfusion. A significant reduction
of MI size was observed when rhEPO was administered 2 hrs after
coronary ligation at the time of reperfusion; Delaying administra-
tion of EPO treatment to 4 hours after reperfusion or 6 hours after
permanent coronary occlusion abolished its effect to reduce an MI
size.
Methods
2-mo old male Wistar rats, obtained from Charles River
Laboratories (Wilmington, MA), were studied in conformance
with the NIH Guide for the Care and Use of Laboratory Animals,
Manual 3040–2 (1996), with NIA Animal Care and Use
Committee approval. Rats were divided into 5 experimental
groups, 10 animals in each. All rats were subjected to open chest
surgery under Isoflurane anesthesia (2% in oxygen) - coronary
artery ligation [21] - and were euthanized 24 hrs after beginning
of coronary occlusion for histological evaluation of infarct size.
The experimental design is illustrated in the Figure 1. In 2 groups
(D, E) the ligature occluding coronary artery remained in place for
24 hrs, in 3 groups (A, B, C) the ligature was released after 2 hrs of
occlusion and the myocardium was reperfused. Rats from one of
the permanent occlusion groups (D) and one of the ischemia/
reperfusion (I/R) groups (B) remained untreated (injected
intraperitoneally with 0.5 ml of saline 2 hrs after coronary
occlusion). Rats from the second I/R group (A) had rhEPO
(3000 IU/kg) administered at the time of reperfusion, i.e., 2 hrs
after occlusion. Rats from the third I/R group (C) had rhEPO
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Figure 1. Diagram of experimental design. In A, B, and C left
descending coronary artery is occluded for 2 hrs and reperfused for
22 hrs. In D and E left descending coronary artery is occluded for 24 hrs.
rhEPO administered 2 hrs after a temporary coronary occlusion at the
time of reperfusion (A), or 6 hrs after a temporary coronary occlusion,
i.e., 4 hrs after beginning of reperfusion (C), or 6 hrs after a permanent
coronary occlusion (E). Physiological saline administered 2 hrs after a
temporary occlusion at the time or reperfusion (B) or 2 hrs after a
permanent occlusion (D).
doi:10.1371/journal.pone.0034819.g001
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34819injected 4 hrs after reperfusion, i.e., 6 hrs after occlusion. In the
second permanent occlusion group rhEPO was also injected 6 hrs
after coronary occlusion. Myocardial area at risk (AAR) and MI
size were measured as previously described [22]. Briefly, 3 mL of
5% Evans blue dye (Sigma) was rapidly injected into the aorta via
a 16-gauge tube to distinguish the perfused area (blue staining)
from the unperfused area (no staining). The atria and great vessels
were dissected away from the heart, and the heart was cut
transversely into 4 slices from base to apex. Heart samples were
incubated at 37uC in 4% triphenyltetrazolium chloride (TTC,
Sigma) for 30 minutes to distinguish the infarct area (unstained)
from the AAR (brick red staining) in the unperfused area. All
images were analyzed with NIH Image software. MI size was
expressed as a percentage of the unperfused area or LV.
Differences among groups were statistically evaluated using one-
way analyses of variance with post-hoc Bonferroni comparison.
Results
MI size 24 hrs after coronary occlusion is illustrated in Figure 2.
AAR was similar in all 5 groups. MI size, expressed either as a
percent of AAR, or as a percent of left ventricle was similar
between untreated I/R and permanent occlusion groups and
averaged 4262% of the AAR or ,24% of LV. MI size in the
group treated at the time of reperfusion was reduced by more than
50% (1962% of the AAR or 9% of LV, p,0.0001). However, MI
size in groups in which EPO treatment was delayed by 4 hrs after
reperfusion or by 6 hrs after permanent coronary occlusion did
not differ from MI size of untreated animals.
Discussion
In the recently completed clinical trial, REVEAL [17,18]
patients received 60,000 IU of rhEPO (approximately 750 IU/kg)
within 4 hrs of percutaneous intervention (PCI) (actually within
8 hrs of symptom onset) and treatment was not effective in
reduction of MI size, or in attenuation of cardiac remodeling. In
our experiment in a rat model of MI, treatment was very effective,
when rhEPO was injected at the time of reperfusion following
2 hrs after coronary occlusion. However, the MI size in rats was
completely unaffected by treatment if it were delayed by 6 hrs post
occlusion, regardless whether reperfusion was performed or the
coronary artery remained occluded. Thus in our animal
experiment, designed to imitate the design of the REVEAL
clinical trial, application of rhEPO failed to reduce the MI size.
Most of other clinical trials (see Table 1) have the same design
problem as REVEAL, i.e., delayed treatment. Even in trials when
EPO was injected at the time of PCI, the time from the symptom
onset was sometimes as long as 24 hrs. In the only trial with an
encouraging outcome [19], the EPO was injected at the time of
PCI and the PCI was done within 6 hrs of the beginning of
symptoms.
Among numerous experimental studies of cardioprotection by
rhEPO, very few were specifically designed to establish a
therapeutic window. But in one study in the rat model of MI
induced by a permanent coronary occlusion Moon et al [23] had
shown that a high dose of rhEPO (3000 IU/kg) can be effective in
reduction of MI size, if injected not later than 12 hrs after
coronary occlusion. However, a small dose (150 IU/kg), which is
equivalent to 10000–15000 IU for a human of average body
weight, was effective only if administered at the time of
occlusion. Similar results were reported by Hirata et al [24] in
experiments with a permanent ligation of a coronary artery in dogs
– MI was reduced if treated at the time of ligation, but not
6 hrs later. It is necessary to note here that in both these studies
the permanent occlusion model was used. In most of experiments
reporting beneficial effect of EPO on MI size in animal models of
ischemia/reperfusion injury treatment was administered at the
time of reperfusion [3,4], i.e., 30–60 min after coronary
occlusion.
Positive outcome of therapeutic interventions in experiments on
animal models of disease cannot assure that similar interventions
will be successful in patients. In contrast, there is no doubt that an
intervention that failed to affect improvement in the animal model
will be unsuccessful in patients. Therefore, while our findings
cannot assure that species differences in response to therapy will
not affect the outcome of human clinical trials, they strongly
suggest that a reason for failure in rhEPO clinical trials in patients
with acute MI might have been a difference in their design, i.e.,
the timing of drug administration substantially deviated from that
of preclinical animal experiments. The discrepancy in design
between preclinical and clinical trials was certainly influenced by
regulatory and ethical issues justifiably associated with conducting
a clinical trial involving a patient in an emergency clinical setting
resulting in difficulties to obtain informed consent early enough.
Another reason for this discrepancy may be the lack of creative
interaction between animal researchers and clinicians planning
clinical trial: in an ideal world preclinical animal trials would be
designed to imitate, as close as possible, a clinical situation.
Conversely, clinicians, aiming to initiate a clinical trial, need to
dialog with animal researchers about specific, clinically relevant,
details of their experiments and perhaps request that additional
experiments in an animal model be conducted to resolve
questionable issues prior to finalizing a trial design in humans.
As a bare minimum, pharmacodynamics, pharmacokinetics, dose
response, and therapeutic window (where applicable) must be
established in animal experiments, and this information applied to
the design of a clinical trial.
In summary, a prerequisite condition for a proper clinical trial
of therapeutic efficacy of EPO in acute MI is a short time between
symptom onset and EPO administration. Currently in the USA,
the average symptom onset-to-door time among patients with ST-
Figure 2. Size of myocardial infarction. Area of myocardium at risk
(AAR) and size of myocardial infarction (MI) 24 hrs after permanent
occlusion of the left descending coronary artery or after 2 hrs of
occlusion followed by 22 hrs of reperfusion. rhEPO is administered at
the time of reperfusion (IR-EPO-0 h) or 4 hrs after beginning of
reperfusion (IR-EPO-4 h) or 6 hrs after permanent coronary occlusion
(MI-EPO-6 h). Data presented as means 6 SEM. AAR is presented as %
of left ventricle (LV). MI is presented as % of AAR or % of LV. *- p,0.05
vs all other group (Bonferroni post hoc comparison).
doi:10.1371/journal.pone.0034819.g002
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34819segment elevation infarct is 1.6 hrs and the average door-to-
balloon time is 87 minutes [25]. Thus, a total time from the
symptom onset to a primary PCI is around 3 hrs, which,
according to animal experiment data, approaches or even exceeds
the limits of EPO therapeutic window. Therefore, randomization
and treatment should take place as soon as possible after ST-
elevation is observed and MI is confirmed. If rhEPO were to be
administered before a patient receives PCI, the likelihood of
accessing the therapeutic time window for EPO would be
enhanced.
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